Medimmune Limited

University of Michigan

Systemix, Inc.

The United States of America, As Represented by the Secretary, Department of Health and Human Services

Columbia University

Medimmune Vaccines, Inc.

Memimmune, LLC

Delmar Pharmaceuticals, Inc.

Richard Schwartz

Bernhard O Palsson

Stephen G Emerson

Ajit Subramanian

John Michael Berry

Xiao Shi

George William Kemble

Michael F Clarke

Baoshan Zhang

Ivelin Georgiev

Gwo-Yu Chuang

Mark Connors

Young Do Kwon

Gilad Ofek

Jonathan Edward Liu

George Robert Trager

Mark Thompson

Qi Dang

Srikanth Ranga Chary

Lawrence Shapiro

Mark Louder

Robert Bailer

Sijy O'Dell

Krisha McKee

Tatyana Gindin

Lisa Kueltzo

Simon Sheng-Tsiung Hsu

Mridul Ghosh

Mangaiarkarasi Asokan

Jonathan Cooper

Kevin Carlton

Michael Bender

Amarendra Pegu

Peter D Kwong

Sean Tucker

John R Mascola

Dennis M Brown

William J Garner

John Mascola

Jeffrey A Bacha

Luis J Maranga

Mohammed A Elkalay

Suzanne Chang Kuo

Luis Jorge Camilo Maranga

Shang-Chih David Jen

Donald David Briggs

Weidong Cui

Anne Steino

Kent C Shih

Sareth Kanekal

Howard A Burris

Simon Hsu

Neutralizing antibodies that specifically bind to HIV-1 Env and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

10E8 neutralizing antibody variants that bind to the MPER region of HIV-1 GP41 and their use

Neutralizing antibodies to HIV-1 GP41 and their use

The present invention relates to novel MDCK cells which can be to grow viruses, e.g., influenza viruses, in cell culture to higher titer than previously possible. The MDCK cells can be adapted to serum-free culture medium. The present invention further relates to cell culture compositions comprising the MDCK cells and cultivation methods for growing the MDCK cells. The present invention further relates to methods for producing influenza viruses in cell culture using the MDCK cells of the invention.

MDCK cell lines supporting viral growth to high titers and bioreactor process using the same

The present invention provides novel MDCK-derived adherent non-tumorigenic cell lines that can be grown in the presence or absence of serum. The cell lines of the present invention are useful for the production of vaccine material (e.g., viruses). More specifically, the cell lines of the present invention are useful for the production of influenza viruses in general and ca/ts influenza viruses in particular. The invention further provides methods and media formulations for the adaptation and cultivation of MDCK cells such that they remain non-tumorigenic. Additionally, the present invention provides methods for the production of vaccine material (e.g., influenza virus) in the novel cell lines of the invention.

Non-tumorigenic MDCK cell line for propagating viruses

Methods and compositions for the optimization and production of refrigerator-temperature stable virus, e.g., influenza, compositions are provided. Formulations and immunogenic compositions comprising refrigerator-temperature stable virus compositions are provided.

Refrigerator-temperature stable influenza vaccine compositions

Method of purifying influenza virus and removing MDCK cell DNA contaminants

Methods and compositions for the optimization and production of influenza viruses, e.g., ca influenza B strains, in eggs and host cells suitable as influenza vaccines are provided.

Methods of producing influenza vaccine compositions

Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.

The separation device of the invention is directed to a container having an interior surface defining a channel. The container further has an inlet and an outlet. On the interior surface of the channel are pole tips which may be in a sawtooth configuration having sharp angles facing the interior of the channel that generate a high gradient magnetic field in the channel. Within the channel may be incorporated separating material. The separating material eliminates the direct contact of cells with the magnetic pole material. The separating material, as well as the sawtooth pole tips also serves the purpose of creating a field gradient across the entire container to avoid the problem of zero field gradient in the center of the container where the velocity is greatest, and where more cells flow. The separating material is designed to cause a substantially unobstructed flow of medium through the channel so that unlabeled substances are not trapped in the separating material.

High gradient magnetic device and method for cell separation or purification

Methods, compositions and devices are provided for the growth of human stem and/or hematopoietic cells in culture. Bioreactors are provided in which diverse cell types are simultaneously-cultured in the presence of appropriate levels of nutrients and growth factors substantially continuously maintained in the bioreactor while removing undesirable metabolic products. This simultaneous culture of multiple cell types successfully reconstructs hematopoietic tissue ex vivo. Optionally, at least one growth factor is provided through excretion by transfected stromal cells, particularly heterologous cells. The invention also allows for the separate maintenance of stromal and hematopoietic cells, and to allow for harvesting of both the adherent and non-adherent cells.

Devices for maintaining and growing human stem and/or hematopoietics

Methods, compositions and devices for maintaining and growing human stem

Growing community of inventors

Bethesda, MD, United States of America

Richard Schwartz